FCX vs SRPT · P/E 38, rev $25.45B vs rev $1.90B
Freeport-McMoran Copper & Gold Inc (FCX) versus Sarepta Therapeutics Inc (SRPT) — a side-by-side from cached financials, not a winner call.
Freeport-McMoran Copper & Gold Inc (FCX) is a copper company listed on US.
Sarepta Therapeutics Inc (SRPT) is a biotechnology company listed on US.
Latest reported FCX revenue for 2024-12-31 was $25.45B. Net income was $4.40B. Revenue was up 11.4% from 2023-12-31 to 2024-12-31. FCX currently screens at market cap $67.80B and trailing P/E 38.0.
Latest reported SRPT revenue for 2024-12-31 was $1.90B. Net income was $235.2M. Revenue was up 53.0% from 2023-12-31 to 2024-12-31. SRPT currently screens at market cap $2.34B.
FCX currently screens at market cap $67.80B and trailing P/E 38.0. SRPT currently screens at market cap $2.34B.
Not investment advice. Open the FCX and SRPT stock pages for the full models.
Not investment advice.